Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease: A Giant Leap-To Start with Baby Steps
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease: A Giant Leap-To Start with Baby Steps ; volume:41 ; number:05 ; year:2020 ; pages:733-734
Indian journal of medical & paediatric oncology ; 41, Heft 05 (2020), 733-734
- Contributor
-
Singh, Suvir
- DOI
-
10.4103/ijmpo.ijmpo_275_20
- URN
-
urn:nbn:de:101:1-2021082712024825163695
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Singh, Suvir
Other Objects (12)
Ruxolitinib in Glucocorticoid Refractory Chronic Graft versus Host Disease
Small steps for workers, a giant leap for productivity
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis
Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis
The Leap (No Leap)
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
Efficacy and safety of ruxolitinib in the treatment of chronic graft-versus-host disease: a retrospective analysis
Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
Leap year
Leap Next
Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients
Ruxolitinib in Glucocorticoid Refractory Chronic Graft versus Host Disease
Small steps for workers, a giant leap for productivity
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis
Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis
The Leap (No Leap)
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
Efficacy and safety of ruxolitinib in the treatment of chronic graft-versus-host disease: a retrospective analysis
Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
Leap year
Leap Next
Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients
Ruxolitinib in Glucocorticoid Refractory Chronic Graft versus Host Disease
Small steps for workers, a giant leap for productivity
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis
Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis
The Leap (No Leap)
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
Efficacy and safety of ruxolitinib in the treatment of chronic graft-versus-host disease: a retrospective analysis
Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
Leap year
Leap Next